VIRAL PARTICLE RELEASED AFTER INFECTION OF HUMAN CYTOMEGALOVIR (HCMV) OF MAMMALS CELLS, CONTAINING FUSION PROTEIN, AND ITS APPLICATION Russian patent published in 2017 - IPC C12N7/04 C12N15/869 A61K39/245 

FIELD: biotechnology.

SUBSTANCE: invention relate to the virus particle is released after infection of human cytomegalovirus cells (HCMV), its use in the prevention or treatment of disease by the formation of neutralising antibodies against at least one antigenic heterologous peptide or by induction of CD8+T-lymphocyte response against such heterologous peptide and a vaccine comprising such a viral particle. The characterized viral particle is surrounded by a lipid membrane in which viral glycoproteins are shipped and contains neither viral DNA nor capsids. The particle comprises a fusion protein comprising one or several parts T-cell antigen pp65 and at least one heterologous peptide, and wherein at least one heterologous peptide amino acid incorporated at position W175 ot A534 of the amino acid sequence of T-cell antigen pp65.

EFFECT: increased efficiency of application.

23 cl, 5 dwg, 5 ex